Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). Additionally, the European Medicines Agency (EMA) granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T. These regulatory designations recognize the significant unmet medical need in A-T and provide development incentives intended to support and accelerate the advancement of promising therapies for rare diseases.

The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individuals from birth through adolescence and meets the statutory definition of a rare disease. The EMA's Committee for Orphan Medicinal Products similarly concluded that NB4168 met the criteria for orphan designation for the treatment of A-T. Together, these designations provide regulatory recognition in the European Union and further support the company's plans to advance the program globally.

NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. It is designed to have significantly higher bioavailability and increase NAD+, a coenzyme essential for DNA repair, mitochondrial function, cellular energy production, and stress responses—biological pathways disrupted in A-T. As A-T is categorized as a rare genetic premature aging disease, NB4168 may translate to other age-related diseases.

Rob Fried, Chief Executive Officer of Niagen Bioscience, stated that receiving RPD Designation from the U.S. FDA and OMPD from the EMA represents meaningful regulatory validation of NB4168 and the company's strategy to develop therapies for patients with serious rare diseases. He noted that these milestones strengthen the path toward clinical development and reinforce the opportunity to extend the company's leadership in NAD+ science into regulated medicines.

About Ataxia Telangiectasia (A-T)

A-T is a rare genetic disease caused by mutations in the ATM gene. The disease typically presents in early childhood and is characterized by progressive loss of motor coordination, impaired immune function, increased susceptibility to infections, pulmonary complications, a substantially elevated risk of cancer, and premature aging. There are currently no FDA-approved therapies for A-T, and treatment is largely limited to supportive care. A-T impacts roughly 1 in 40,000 people in the U.S. and 1 in 150,000 people in Europe.

Regulatory Designations and Development

The FDA's RPD Designation is intended to encourage the development of therapies for serious and life-threatening diseases that primarily affect children. The EMA's OMPD is granted to therapies intended to diagnose, prevent, or treat life-threatening or chronically debilitating rare diseases affecting fewer than five in 10,000 people in the European Union. Niagen Bioscience is currently advancing preclinical development activities and plans to submit an Investigational New Drug (IND) application to the FDA in anticipation of initiating human clinical studies.

Key Details of the NB4168 Program

Niagen Bioscience has filed a prospectus to offer and sell common stock up to $50M. The filing, submitted to the SEC, outlines the company's plans to raise capital through the issuance of shares. This move is part of Niagen Bioscience's broader financial strategy to secure funding for future growth and operations.

Key Details of the Offering

The prospectus provides essential information about the proposed stock offering. Below is a summary of the key details:

Strategic Implications

By filing the prospectus, Niagen Bioscience aims to attract investors and raise capital. The funds generated from the stock offering will likely be used to support the company's operational and expansion initiatives. This filing reflects Niagen Bioscience's commitment to leveraging financial markets to achieve its business objectives.

Next Steps

The prospectus is now available for review by potential investors and regulatory bodies. Niagen Bioscience will proceed with the offering upon meeting all regulatory requirements and securing necessary approvals. The company's leadership is expected to provide further updates as the process advances.